Swiss Medica, Inc.
OTC Bulletin Board : SWME

Swiss Medica, Inc.

January 18, 2006 08:00 ET

Swiss Medica's O24 Pain Neutralizer Is One Of Canada's Top Selling Topical Pain Relief Products

TORONTO, ONTARIO--(CCNMatthews - Jan. 18, 2006) - Swiss Medica, Inc. (OTCBB:SWME) is pleased to announce that according to sales rankings for the latest 52-week period ending November 30, 2005 by ACNielsen, the 30ml spray bottle of O24 Pain Neutralizer was ranked the fourth best selling product in the topical analgesic pain relief category in Canadian drug stores, based on dollar sales at the retail level. O24 Pain Neutralizer was nationally launched in Canadian drug stores in September 2004.

Swiss Medica's Vice President Canadian Sales, Anne Dundon commented "O24 Pain Neutralizer has continued to prove itself in the retail marketplace in Canada. The product is gaining strong acceptance from consumers suffering from muscle aches and pains - plain and simple, this patented all-natural product works."

Swiss Medica's President and COO, Grant Johnson noted "We are extremely pleased with the quick acceptance this product has gained in Canada from consumers, retailers and the medical community within 15 months of national distribution. Our Canadian business recorded just under C$2.0 million in net revenues for 2005 (approximately US$1.7 million) and we expect continued high growth in 2006 as we launch O24 Fibromyalgia and PMS Escape into the Canadian marketplace. In addition, the success of O24 Pain Neutralizer is an excellent indicator of the potential for O24 in the United States as Canada's population is approximately 10 percent the size of that of the United States."

About Swiss Medica, Inc.

Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission is to be a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please visit our websites at , and

Swiss Medica's flagship product, the O24 Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The O24 pain relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits by healthcare professionals and athletes in the United States, Canada and in Europe. O24 is widely available throughout the United States and Canada in leading pharmacies and other retailers. Customers can also visit, for ordering details and store locators for the nearest pharmacy.

Swiss Medica has recently launching the patented O24 Fibromyalgia pain reliever (US Patent #6,444,238B1) over-the-counter in North American retailers. The National Fibromyalgia Association (NFA) recently awarded O24 Fibromyalgia their first NFA Seal of Approval. Upwards of 11 million Americans suffer from the long-term pain associated with Fibromyalgia. In a randomized double blind clinical trial, more than 90 per cent of the patients who used O24 Fibromyalgia reported mild to markedly better improvement, versus only 7 per cent who used the placebo. Customers can also visit, for ordering details and store locators for the nearest retailer.

Swiss Medica also manufactures PMS Escape® which holds US Patent #'s 5760014 and 5612320. PMS Escape® is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce changes in mood and appetite that women experience during the premenstrual period. Customers can also visit: for additional information and ordering details.

Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close transactions being contemplated, risks related to international sales and purchases and potential foreign currency exchange fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information